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INTRODUCTION 
Esophageal varices are Porto systemic collaterals that link between 
Porto venous and Systemic venous circulations.They are formed due to portal 
hypertension (a progressivecomplication of cirrhosis), at the sub mucosa of the 
lower esophagus.Rupture and bleeding of esophageal varices are the major 
complications of portal hypertension and are associated with a high 
mortality rate.Variceal bleeding accounts for 15-35% of all cases of upper 
gastrointestinal bleeding.Patient with variceal bleeding who had no treatment,the 
risk ofrebleeding is 50%.The presence of esophageal varices correlates with the 
severity of the liver disease.Endoscopic modalities used for treatment are 
endoscopic slerotherapy and band ligation for treatment of acute bleeding and 
secondary prophylaxis. 
AIM AND OBJECTIVES 
To compare the efficacy and safety of endoscopic variceal band 
ligation and sclerotherapy in the management of variceal bleeding due to 
portal hypertension. 
MATERIALS AND METHODS 
The study was conducted in the Department of General Surgery in 
collaboration with the Department of Medical Gastroenterology and 
Department of Vascular Surgery, Coimbatore medical College Hospital 
from June 2013- August 2015. This study was approved by the ethical 
committee of Coimbatore Medical College Hospital. 
STUDY POPULATION: 
50 patients with portal hypertension who were admitted during the 
study period of June 2013 - august 2015 in medicine and surgery wards, 
with the complaints of hematemesis and/or malena, who had grade 3 and 
4 varices without gastric varices and other causes of upper GI bleeding in 
upper GI endoscopy were included in this study. 
RANDOMISATION: 
Every alternative patients presenting with above history is divided 
into 2 groups. One group is treated with esophageal banding and other 
group is treated with 3 % Sodium tetradecyl sulphate after getting 
informed and written consent from the patient. 
INCLUSION CRITERIA: 
 Age 21-70 years 
 Both sexes 
 Grade III and IV esophageal varices 
 Patients complaining with hematemesis and/or malena 
 Due to Portal Hypertension 
EXCLUSION CRITERIA: 
 Age <21 and >70 
 Grade I and II varices 
 Non portal hypertension causes of upper GI bleeding 
 Prior history of endoscopic treatment and shunt operation for 
varices 
 Presence of Hepatic Encephalopathy, Hepatorenal syndrome and 
life expectancy less than 48 hours 
 Patients with positive serology for Hepatitis B (HbsAg) and C 
virus (anti HCV) 
CONCLUSION 
 Both banding and 3% sodium tetradecyl sulphate are equally 
effective in controlling acute variceal hemorrhage among which 
sclerotherapy had a small advantage and also in preventing 
rebleeding. 
 Both banding and sclerotherapy are effective in eradicating varices 
but banding is more efficacious 
 Both banding and sclerotherapy have their side effects but 
sclerotherapy has more frequent and dreaded complications. 
 Hence banding is superior to sclerotherapy both in efficacy and 
safety 
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INTRODUCTION 
Esophageal varices are Porto systemic collaterals that link between 
Porto venous and Systemic venous circulations. 
They are formed due to portal hypertension (a progressive 
complication of cirrhosis), at the sub mucosa of the lower esophagus. 
Rupture and bleeding of esophageal varices are the major 
complications of portal hypertension and are associated with a high 
mortality rate. 
Variceal bleeding accounts for 15-35% of all cases of upper 
gastrointestinal bleeding. 
Patient with variceal bleeding  who had no treatment,the risk of 
rebleeding is 50%. 
The  presence of esophageal varices correlates with the severity of 
the liver disease. 
Endoscopic modalities used for treatment are endoscopic 
slerotherapy and band ligation for treatment of acute bleeding and 
secondary prophylaxis. 
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Since banding therapy has low rate of complications such as 
esophageal stenosis, rebleeding and mortality ,this method is preferred as 
the treatment of choice by many authors. 
Thereby in this study we compare the results of endoscopic 
banding and sclerotherapy with 3% sodium tetradecyl sulphate in the 
management of esophageal varices. 
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AIM AND OBJECTIVES 
    To compare the efficacy and safety of endoscopic variceal band 
ligation and sclerotherapy in the management of variceal bleeding due to 
portal hypertension. 
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REVIEW OF LITERATURE 
ESOPHAGEAL VARICES: 
Esophageal varices is defined as  dilated sub  mucosal veins in the 
lower third  of the esophagus. They are most often due to portal 
hypertension, caused by cirrhosis. Normal portal pressure is 
approximately 9 mmHg. If the portal pressure rises above 12 mmHg, this 
gradient rises to 7-10 mmHg at the inferior vena cava(normal 3-7mmhg). 
A gradient greater than 5 mmHg is considered portal hypertension. At 
gradients even greater than 10 mmHg, blood flow through the hepatic 
portal system is redirected from the liver into areas with lower venous 
pressures. That means the collateral circulation develops in the lower 
esophageous. The small blood vessels in these areas become distended, 
becoming more thin- walled, and starts to bleed due to high pressure 
leading to esophageal varices. 
GRADING (CHILD’s CRITERIA): 
I. Visible veins but not elevated 
II. Large and raised veins but not touching each other 
III. Raised and tortuous almost touching each other 
IV. Very large veins touching each other 
18 
 
ANATOMY OF ESOPHAGUS: 
             It’s a muscular tube of approximately 25 cm long, occupying the 
posterior mediastinum. It extends from upper esophageal sphincter 
(cricopharyngeous muscle)at the level of C6 to the junction of the cardiac 
of the stomach at the level of T11 thoracic vertebra and descends along 
the vertebral column. It also presents with flexures corresponding to the 
curvature at the cervical and thoracic  vertebral column which is the 
narrowest part of the esophagus.  
RELATIONS: 
CERVICAL: 
Anterior: 
 Trachea 
 Thyroid gland 
Posterior: 
 Longus colli muscle 
 Vertebral column 
On Left: 
 Thoracic duct 
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On either side: 
 Part of lobes of Thyroid gland 
 Common carotid artery 
THORACIC: 
Anterior: 
 Trachea 
 Aortic arch 
 Pericardium0 
 Left bronchus 
Posterior:  
 Longus colli muscle 
 Vertebral column 
 Hemiazygous vein             
 Right Posterior intercoastal arteries 
 Thoracic duct 
Right:  
 Azygous vein 
 Vagus nerve 
 Right Pleura 
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Left: 
 Thoracic duct 
 Left subclavian artery 
 Left Recurrent laryngeal nerve 
 Descending thoracic duct 
 Left Pleura 
ABDOMINAL PORTION: 
 It is about 1.5 cm and situated at the posterior surface of left lobe 
of liver in the esophageal groove. 
HISTOLOGY: 
It has four layers 
Mucosa 
Submucosa 
Muscle layer 
Outer fibrous layer 
21 
 
 
Fig.1: Layers of Esophagus 
MUCOSA: 
 Epithelium 
 Basement membrane 
 Lamina propria 
 Muscularis mucosa 
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Fig2: Esophageal Wall 
 Lamina propria-contains lymphatic capillaries, blood vessels and 
loose connective tissue. 
 Muscularis mucosa- thin,double layered mostly abundant at the 
lower part of the esophagus 
Z LINE: 
Is the transition of esophageal mucosa to columnar epithelium at the 
distal 2cm of the esophagus. 
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SUBMUCOSA: 
 It is highly vascular and has loose connective tissue. It is a 
pavement for malignancies since it is  highly vascularised  and  also has 
lymphatic structures with Meissner’s neural plexus. This is the layer were 
dilatation of veins in esophageal varices occur. 
MUSCULARIS EXTERNA: 
Top third-Skeletal muscles 
Middle  - smooth and Skeletal muscle 
Lower third-Smooth muscle 
 
 
 
 
Fig3: Muscularis Propria 
It consists of two layers: 
 Outer Longitudinal 
 Inner Circular 
Auerbach’s or Myentric plexus is present between the muscle layers. 
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GASTRO ESOPHAGEAL JUNCTION: 
 It is a complex valve consisting of smooth muscles(LES) and 
diaphragmatic element. It maintains competence during static condition 
and also during dynamic stress. 
It has four anatomic points: 
 2 Endoscopic 
 2External 
Endoscopic – Z Line 
Transition from smooth muscle to rugae of stomach 
 
 
 
 
 
 
Fig4: Gastroesophageal Junction 
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Externally: 
 Collar of Helvetius(Willis Loop)- where circular fibres of 
esophagus joins with oblique fibres of stomach 
 Gastro Esophageal fat pad 
BLOOD SUPPY: 
Inferior Thyroid Arteries: Cervical Esophagus 
 The cervical esophagus is supplied by the paired inferior thyroid 
arteries. They arise from the thyrocervical trunk of the subclavian artery. 
The inferior thyroid arteries give off branches 2 cm to 3 cm long called 
tracheoesophageal arteries. These travel caudal and medial on each side 
toward the tracheoesophageal groove 
Tracheobronchial and Bronchoesophageal Arteries: Intrathoracic                           
Esophagus 
The intrathoracic esophagus receives blood from two sources, the 
unpaired tracheobronchial arteries, which arise as a group from the 
concavity of the aortic arch  and can number between one and four; and 
the bronchoesophageal artery. 
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Aortic Proper Esophageal Artery: Intrathoracic Esophagus 
Left Gastric and Splenic Arteries: Abdominal Esophagus 
The abdominal esophagus and gastric cardia are supplied by the unpaired 
left gastric  and splenic arteries.These derive from the celiac axis  With as 
many as 11 arterial branches, the left gastric artery mainly supplies the 
anterior and right lateral aspects of the esophageal wall 
 
 
                                
 
 
 
 
 
 
 
Fig5: Arterial Supply of Esophagus 
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VENOUS DRAINAGE: 
 
     
 
 
 
 
 
 
 
 
Fig6: Venous Supply of Esophagus 
 Two small veins usually accompany the circumferential arteries in 
the lamina submucosa. Perforating veins originating from the small 
communicating veins of the submucous plexus pierce the muscular wall 
of the esophagus together with the perforating arteries. They receive 
tributaries from the muscle coats and form the extramural, extrinsic veins 
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at the surface of the esophagus. No valves were found in the esophageal 
venous circulatory system. 
 The extrinsic veins drain into the locally corresponding large 
vessels. The superior vessels drain to the jugular veins or the azygos and 
hemiazygos veins. The inferior veins terminate in the left gastric and 
splenic veins. 
LYMPHATICS: 
 The lymphatic trunks at the surface of the esophagus may drain 
into the regional lymph nodes. Lymph from the esophagus most likely 
drains into the following lymph nodes 
 Paratracheal 
Tracheobronchial bifurcation
Juxtaesophageal 
Intraaorticoesophageal 
The lymph of the abdominal esophagus empties into the following lymph 
nodes: 
 Superior gastric 
Pericardiac 
Inferior diaphragmatic 
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Fig7: Lympahtic Drainage of Esophagus 
NERVE SUPPLY: 
 Innervated by both visceral components of the autonomic nervous 
system, the sympathetic and the parasympathetic systems, which exert 
mutually antagonistic influences on the viscera. The sympathetic efferent 
pathways, common in the gut, are concerned with vasoconstriction, 
contraction of sphincters, and relaxation of the muscular wall. The 
parasympathetic efferent fibers increase the glandular and peristaltic 
activity of the gut 
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Fig8: Nerve Supply of Esophagus 
EMBRYOLOGY: 
            In the human, the primitive foregut forms during the fourth week 
of gestation by a longitudinal folding and incorporation of the dorsal part 
of the yolk sac into the embryo. 
 
 
 
 
 
Fig9: Development of Esophagus 
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 Gut formation 
 Gut molecular regulation 
 Endodermal differentiation 
        In the human, the primitive foregut forms during the fourth week of 
gestation by a longitudinal folding and incorporation of the dorsal part of 
the yolk sac into the embryo. The trachea develops from the foregut about 
22-23 days after fertilization as a median ventral diverticulum. 
Immediately after this diverticulum forms, the stomach develops further 
distally by an asymmetrical extension 
 Foregut 
Several phenomena take place at approximately the 34th day. The 
genesis of the submucosal and muscular layers of both trachea and 
esophagus begins. The distal esophagus elongates first, followed by the 
proximal. Characteristically, the elongated esophageal segment carries 
the gastric-dilated primordium below the forming diaphragm. Most 
likely, however, elongation results from pharyngeal ascent rather than 
gastric descent. 
Separate growth processes of the trachea and esophagus occur 
before the fifth week of intrauterine life. The esophagus attains its final 
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dimensions in the seventh week. At birth its length is 8-10 cm, which 
doubles in the first few years of life.  
Early in the sixth week, the mesenchymal circular muscle coat 
develops. Three to nine weeks later, longitudinal musculature appears. 
During the 4th month, the muscularis mucosa appears. Blood vessels 
enter the esophageal wall during the seventh month, and lymph 
capillaries enter the wall between the third and fourth months of life after 
birth.7  
At the seventh to eighth week the esophageal lumen is almost filled 
with cells from the proliferated esophageal epithelium. Because the filling 
is never complete and small vacuoles are present, the so-called solid stage 
does not exist as such. Around the 10th week the lumen is restored since 
the vacuoles coalesce. 
Changes are also taking place in the esophageal ciliated epithelium, 
which becomes stratified squamous in the proximal and middle 
esophagus. Columnar epithelium remains unchanged in the distal 
esophagus.  
The esophageal wall receives both sympathetic (thoracic trunk and 
celiac plexus) and parasympathetic (vagus nerve) innervation 
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 PORTAL HYPERTENSION: 
Portal hypertension is increased blood pressure in the portal vein 
system, which is composed of the portalvein, and its branches and 
tributaries. Portal hypertension is defined as elevation of hepatic venous 
pressure gradient to >5mmHg 
Elevated pressure is because of, 
 Increased pressure gradient for blood flow in liver 
 Blood flowing in alternating channels  
Patients develop symptoms once pressure raises above 10 mm hg 
CAUSES:  
           PREHEPATIC: 
 Portal vein thrombosis 
 Splenic vein thrombosis 
 Malignant occlusion 
 Massive splenomegaly 
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   HEPATIC: 
  PRE- SINUSOIDAL 
 Schistosomiasis 
 Congenital hepatic fibrosis 
                    SINUSOIDAL 
 Cirrhosis 
 Alcoholic hepatitis 
                  POST SINUSOIDAL 
 Veno-occlusive disease 
POST HEPATIC: 
 Budd chiari syndrome 
 Inferior vena caval webs 
 Veno-occlusive disease 
  Cardiac causes 
o Restrictive cardiomyopathy 
o Congestive pericarditis 
o Severe congestive heart failure 
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                 Portal vein drains the deoxygenated blood from instestine, 
stomach, pancreas, spleen and gall bladder. It is formed by splenic vein 
and superior mesenteric vein. Superior mesenteric vein drains the entire 
small bowel, ascending colon and a part of the descending colon and the 
head of pancreas. 
                Inferior mesenteric vein joins the splenic vein and hence drains 
the tranverse colon and part of descending colon and upper two third of 
the rectum. Hence the Portal vein receives blood from the entire 
gastrointestinal tract. 
 
 
 
 
 
 
 
 
                            Fig 10: Anatomy of Portal Vein 
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                Patients with pressure gradient >12 mm Hg are at high risk of 
variceal bleeding. 
  The major complication of portal hypertension is: 
 Massive upper GI bleeding due to ruptured esophageal varices and 
portal hypertension gastropathy. 
 Ascites 
 Hepatorenal syndrome 
 Hepatic encephalopathy 
CLINICAL COURSE OF VARICEAL BLEEDING 
 Portal hypertension causes porto systemic collaterals development 
among which esophageal and gastric varices are dangerous because their 
rupture causes variceal hemorrhage which is the most lethal complication 
of cirrhosis. 
 When cirrhosis is diagnosed, about 25-45% of compensated 
patients have varices and 65% of decompensated have varices. 80% of 
cirrhotic patients develop esophageal varices in their lifetime and among 
them 35% bleed. Once cirrhosis is found, the incidence of new varices is 
7% per year. Varices increases in size before they rupture and bleed. 
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 Rate of progression of varices range from 10-35% per year. This 
variability is due to inter observer variability, decompensated cirrhosis 
(CHILD b/c), alcoholic etiology, selection of patients and presence of red 
spots at the esophageal varices. 
 The most important factors are variceal size, severity of liver 
dysfunction and red wale markings. The North Italian Endoscopy 
Club(NIEC) index allows the classification of patients into different 
groups with a predicted 1 year bleeding risk. According to the NIEC 
index, patients with small varices and advanced liver disease are at high 
risk of early bleeding. The probability of bleeding within 1 year in Child 
Pug class A patients with large varices and red sign is 24%, but in Child-
Pug C patients with small varices and no red signs, Incidence of bleeding 
within 1 year is 25%. 
              Variceal size is the most useful predictor for variceal bleeding. 
Variceal size and red signs denote the variceal wall tension which is the 
factor determining variceal rupture. Risk of bleeding is very low(1-2%) in 
patients without varices and increases to 6% per year among patients with 
small varices. It increases to 18% per year in patients with medium or 
large varices. Red sign is another predictor of variceal bleeding. Studies 
have shown that variceal bleeding occur if the HPVG reaches a threshold 
of 12mmHg. If the HPVG is reduced (below 12mmHG or >20% of the 
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baseline levels), there is a marked reduction in the risk of bleeding, 
spontaneous bacterial peritonitis, development of ascites and death. 
          Variceal bleeding is the second most common of mortality among 
the cirrhotic patients. In cirrhotic patients, variceal bleeding causes 60% 
of upper digestive bleeding. Mortality from variceal bleeding has greatly 
decreased from 42% to 6-12% over the last two decades according to 
Graham and Smith study in 1981. This is due to implementation of 
effective endoscopic and pharmacological therapies, Trans jugular 
intraheapatic portosystemis shunt (TIPS) and improved general medical 
care. Death occurring within 6 week from the hospital admission for 
variceal bleeding is considered as a bleeding-related death. 
                Immediate mortality from uncontrolled bleeding is about 4% to 
8 %. Prehospital mortality from variceal bleeding is 3%. Other causes for 
mortality are due to kidney failure, heapatic encephalopathy ,infection, 
poor liver function, severe portal hypertension with HPVG>20 mmHg  
and active bleeding at endoscopy. 
MANAGEMENT OF VARICES: 
 Conservative  
 Pharmacological 
 Decompressive shunts 
 Devascularisation procedure 
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 Endoscopic therapy 
 Liver transplantation 
Conservative Management: 
 A Sengstaken–Blakemore tube is a medical device inserted 
through the nose or mouth and used occasionally in the management 
of upper gastrointestinal hemorrhage due to esophageal varices. The 
device consists of a flexible plastic tube containing several internal 
channels and two inflatable balloons. Apart from the balloons, the tube 
has an opening at the bottom (gastric tip) of the device. More modern 
models also have an opening near the upper esophagus; such devices are 
properly termed Minnesota tubes. The tube is passed down into 
the esophagus and the gastric balloon is inflated inside the stomach. A 
traction of 1 kg is applied to the tube so that the gastric balloon will 
compress the gastroesophageal junction and reduce the blood flow to 
esophageal varices. If the use of traction alone cannot stop the bleeding, 
the esophageal balloon is also inflated to help stop the bleeding. The 
esophageal balloon should not remain inflated for more than six hours, to 
avoid necrosis. 
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Pharmacological Therapy: 
 Non cardio selective beta blocker 
 Vasopressin, terlipressin 
 Somatostatin analogue 
NON CARDIO SELECTIVE BETA BLOCKER: 
a. Propanolol 
b. Nadolol 
                These drugs were introduced by Lebrec and his colleagues in 
early 1980 to reduce portal hypertension which is the mainstay of 
prophylactic therapy. 
Advantage: 
         It plays a major role in preventing the initial bleed, managing acute 
variceal bleed and also first line in preventing rebleeding. 
Disadvantages: 
                 It had limited use in patients with Kidney disease, heart 
disease, astma and other lung diseases, diabetes and drug allergies. 
 
 
41 
 
VASOPRESSIN AND TERLIPRESSIN: 
                These drugs are used at acute variceal bleeding by reducing the 
portal pressure. Vasopressin has significant side effects with systemic 
vasoconstriction. So it is largely replaced by terlipressin. 
SOMATOSTATIN AND ANALOGUE (OCTREOTIDE): 
                These are synthetic analogues of stomatostatin which act by 
inhibiting the release of vasodilatory hormones and also causing 
splanchnic vasoconstriction which in turn lowers the portal blood flow 
thereby decreasing bleeding and preventing rebleeding. 
DECOMPRESSIVE SHUNTS: 
                     Decompressive is mostly used as a second line and is 
reserved only who rebleed after endoscopic therapy and beta blockers. 
Surgical shunts are of 3 categories: 
 Total shunt 
 Partial shunt 
 Selective shunt 
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TOTAL SHUNT: 
 Classical end to side portocaval shunt 
 Side to side porto caval shunt 
                Shunt size need to be atleast 10mm in diameter. Both are 
effective in controlling varices but especially end to side shunt is more 
effective then side to side while only the latter is effective in controlling 
ascites. 
 Disadvantages: 
               These shunts are associated with increased incidence of Hepatic 
encephalopathy. 
PARTIAL SHUNT: 
                Shunt size is about 8mm. Polytetrafluroethylene (PTFE) 
interposition the grafts between portal vein and inferior venacava found 
to be greater than 90% control of varices and maintain portal perfusion. 
SELECTIVE SHUNTS: 
 Distal Splenorenal Shunt (DSRS), THE WARREN SHUNT: 
                 In patients who have impaired hepatic reserve, the Warren 
shunt has been proposed as an effective operation because it 
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decompresses the esophageal varices without disturbing portal perfusion 
of the liver. It is the anastomoses between splenic veins with the left renal 
vein after its disjunction with the superior mesenteric vein. Control of 
bleeding and portal perfusion is maintained in more than 95%of 
individuals. Incidence of hepatic encephalopathy after the shunt is around 
15%. 
Transjugular intrahepatic porto systemic shunt (TIPS): 
             TIPS were described by Rosch in 1969 but only in 1982 it was 
first used in humans by Dr.Ronald Calpinto. It became successful only 
with the development of endovascular stents in 1985. From 1988 the 
procedure has widely being accepted and preferred method for treating 
portal hypertension refractory to medical treatment. Hence TIPS widely 
replaced the surgical portocaval shunt. TIPS is the puncture of internal 
jugular vein, passage of catheter into one of the major hepatic 
vein(usually right) through the right atrium followed by transparenchymal 
liver puncture to cannulate the portal vein. 
           Intraparenchymal tract is dilated and is stented with an expandable 
metal stent. Pressure is measured before and after keeping the stent and 
the goal is to attain pressure difference of less than 10mm Hg between 
portal vein and right atrium. The success rate is high with less morbidity. 
44 
 
           Disadvantages of TIPS are its thrombosis and restenosis which 
necessitates frequent repeat procedures and monitoring. The early 
thrombosis is related to bile duct puncture since the bile is extremely 
thrombogenic, occlusion occurs within first 24 hrs. 
DEVASCULARISATION PROCEDURES: 
                  These operative procedures take care of the variceal bleeding 
by interrupting the inflow to the varices. The Sugiura procedure is a 
surgical technique that involves the removal and transection of the blood 
vessels that supply the upper portion of the stomach and the esophagus. 
The procedure also involves a splenectomy. The original technique 
described by Sugiura and Futagawa was a two-step operation consisting 
of an initial thoracic operation followed by the abdominal operation 3–4 
weeks later. The thoracic operation consists of an extensive 
paraesophageal devascularization up to the inferior pulmonary vein and 
esophageal transection. The abdominal operation consists of a 
splenectomy, devascularization of the abdominal esophagus and cardia, 
and a selective vagotomy with pyloroplasty. The advantage is that they do 
not reduce portal hypertension and hence maintaining portal perfusion of 
the cirrhotic liver. The disadvantage is relentless recollateralization of 
varices across the esophageous and stomach with risk of rebleeding. 
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LIVER TRANSPLANTATION: 
             Variceal bleeding per se is not on indication for liver 
transplantation while the associated ascites and encephalopathy are 
indicators of end stage liver disease and for liver transplantation.  
            The timing of transplant is by the severity of the underlying liver 
disease. 
ENDOSCOPIC THERAPY: 
 SCLEROTHERAPY 
 BANDING 
 TISSUE ADHESIVES 
 ENDOLOOPS 
 BALLOON TAMPONADE 
 CYANOACRYLATE GLUE INJECTION 
ENDOSCOPIC SCLEROTHERPY: 
HISTOLOGICAL ASPECTS: 
                  Endoscopic sclerotherapy for esophageal varices was first 
reported by two Swedish surgeons Crafoord and Freckner in 1939 in 19 
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yr old female using Quinine as sclerosant every alternate day for one 
month till the varices obliterated. Then in 1940, a thoracic surgeon 
Moensch at Mayo clinic reported the second case of sclerotherapy  
 
Fig 11: Endoscopic Sclerotherapy 
SCLEROSING AGENTS: 
              Sclerosing agents were actually used in 1920 for varicose veins 
of lower limbs. The choice of sclerosants depends on the number of 
considerations including the efficacy of the agent, injection techniques, 
safety profile, availability and cost. 
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 The sclerosing agents available are: 
          SYNTHETIC PRODUCTS 
 Sodium tetradecyl sulphate 
 Polidocanol 
           FATTY ACID DERIVATIVES 
 Sodium morrhuate 
 Ethonalamine oleate 
           OTHER AGENTS 
 3%phenol in water 
 5%phenol in oil 
 Absolute alcohol 
FACTORS INFLUENCING SCLEROTHERAPY: 
                A number of factors influence the effect of sclerotherapy on 
esophageal varices which includes choice of endoscope, injection sites, 
timing of the injection, amount and type of sclerosant used and clinical 
condition of the patient. 
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MECHANISM OF ACTION: 
  The mechanism of action of these agents are poorly defined but the 
effects involve more than simple initiation of the clotting process of 
intimal injur. Autopsy studies showed that the thrombosis of the 
submucosal vessel occur within in the first 24 hours along with tissue 
necrosis even in the absence of extravasations of these agents, while 
superficial or deep ulceration occurs after seven days. Submucosal 
fibrosis was seen one month of sclerotherapy. 
             These extravasation effects may be responsible for the long time 
success of sclerotherapy with the development of fibrosis preventing the 
formation of new variceal channels in the adjacent mucosa. Hence, 
procedures which are directed only at the varices often fail because of 
subsequent ligation of collaterals. Sclerotherapy achieves hemostasis 
through a tamponade effect and also by induction of local thrombosis 
followed by sclerosis due to sclerosant. 
SODIUM MORRHUATE: 
          Sodium morrhuate, is sodium salt of the fatty acid in cod liver oil 
was first described in 1993.  It is available in 5% solution.  It is being less 
irritating to the adjacent tissues than phenol and quinine mixtures which 
were in use at that time.  Studies shows rebleeding rate was 17%, 
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 Ulceration were seen in 23%, fere in 28% and pleural effusion in 
7% and esophagopleural fistula in 4%.  Although sodium morrhuate 
appears to be an effective sclerosing agent the incidence of deep post 
sclerosis ulceration and other serious complication is clearly a restricting 
factor in its use. 
ETHANOLAMINE OLEATE: 
  Ethanolamine oleate is derived from oleic acid and is similar in 
physical properties to sodium morrhuate.  It is also available in 5% 
solution. Johnston and Rodgers used 5% ethanolamine oleate in their 
experience of 15 yers reported rebleeding rate of 7% and a mortality of 
18%. 
 The most common complications were pyrexia which was seen in 
39% and retrosternal discomfort which was seen in 30% of patients. Even 
though ethanolamine oleate enjoys a good reputation as a sclerosing 
agent, the data available at present would not appear to give this drug a 
clear advantage in either safety or efficacy over other agents. 
ALCOHOL: 
 The advantage of alcohol is its easy availability and economy.  The 
success rate in controlling the variceal bleed was 92% with rebleed rate of 
32%. There is a higher complication rate with an intravariceal  injection 
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of absolute alcohol most commonly ulcerations. Through alcohol may 
appear to be an effective sclerosing agent, the higher incidence of severe 
retrosternal pain, dysphagia, ulcers and stricture is clearly a restricting 
factors in its use. 
PHENOL: 
 Supe in 1994 used 3% aqueous phenol for sclerotherapy of 
esophageal variceal bleeding. Preobliteration variceal bleeding appeared 
in 15% of the patients.  Complication such as esophageal ulceration, 
stricture and perforation were observed in 32%, 4.5% and 1% of the 
patients. Complication such as esophageal ulceration, stricture and 
perforation were observed in 32%, 4.5% and 1% of the patients 
respectively.  Though it is cheap and freely available, because of the high 
complication rate, use of phenol as a sclerosing agent was given up. 
POLIDOCANOL: 
 Hydroxypolyethyoxydodecan (HPD) or polidocanol is 
commercially available as aethoxysclerol.  It is a synthetic product 
available in uniform lots.  It is marketed as 0.5%, 1,2,3% solutions.  
Paquet has concluded by his study that 1% polidoconal was associated 
with decreased rate of complication.  Deep ulcerations were seen in 11 
patients out of 640 patients, while superficial ulceration occurred in 30 
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patients, pleural effusion in 14 patients.  Minor complication like 
retrosternal pain were observed in 15% of the patients.  Sorensen et al., 
described a higher rate of esophageal stricture (59%) with the use of 3% 
polidocanol especially when more treatment sessions and greater amount 
of scerosants were used18.  
SODIUM TETRADECYL SULPHATE: 
  Sodium tetradecyl sulphate was first suggested as a  a sclerosing 
agent in 1946. Reiner noted that the agents in use at that time, such as 
sodium morrhuate, were soaps of naturally occurring oils and allergic 
reaction did occur ranging from rash to anaphylaxis.  Surface activity of 
the fatty acid anions of the soap was believed to be physical activity 
responsible for thrombosis.  This activity was enhanced in this synthetic 
anionic detergent, sodium tetradecyl sulphate. 
 Hence being a detergent based chemical, its action is on the lipid 
molecules in the cells of the vein wall watch result in the destruction of 
the internal lining of the vein and eventual sclerosis of the vine.  It is 
available in the concentrations of 0.2%, 0.5%, 1.0%, 1.5%, and 3.0%. 
Solutions. 
 Sodium tetradecyl sulphate occurs as white waxy solid. Sotradecol 
is a sterile non pyrogenic solution of sodium tetra decyl sulphate which is 
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used as a sclerosing agent. These drugs are widely used for varicose 
veins. 
ADVERSE EFFECTS: 
                 Local reactions such as pain, ulceration are common at the site 
of injection. Systemic reactions reported are headache, nausea, vomiting. 
Allergic reactions like asthma, hay fever and anaphylactic shock were 
also reported. Six deaths have been reported among which anaphylactic 
shock accounts for four patients, one is due to asthma and the last is due 
to its concomitant use with anti-ovulatory agents. 
            Blenkinsopp showed that 3% STD  was  efficacious than 1% but 
due  to damage to arterial wall  was  seen  at both 1% and 3% 
concentrations but at a lesser incidence compared to other sclerosants. 
This is of interest because the bleeding from deep ulcerations  following  
sclerotherapy was to be related to arterial damage rather due to portal 
hypertension. Post sclerotherapy ulcerations were found to be superficial 
ulceration. Thus sodium tetradecyl sulphate can be considered as one of 
the potent sclerosing agent at present. 
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TECHNIQUE: 
             There is no accepted standard technique for sclerotherapy 
injections. One disparity lies between paravariceal and intravariceal 
injection. 
Intravariceal technique: 
                 It is known as Anglo-American method. Sclerosants are 
directly injected into varices. All visible varicies are injected with 1-2 ml 
of sclerosant directly then with 1-2ml 1cm below the bleeding site. Then 
1 ml of sclerosant is injected at gastro esophageal junction along all the 
varices. Even though the varices are present more proximally injections 
are placed up to 10 cm from gastro esophageal junction in 3-5 cm 
intervals unless a more proximal bleeding site is identified since the 
sclerosant can escape from varix into the azygous system and then into 
pulmonary circulation. Total volume of sclerosant should never exceed 
20 ml per session or 5 ml per varix. 
Paravaricel technique: 
         It is known as Europen approach. In this technique sclerosant is 
injected into the adjeacent submucosa of the visible varices. At first 
slerosant is injected at the gastro esophageal junction and it is repeated 
circumferentially upto 10 cm proximally in a spiral fashion. The 
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advantages is that it controls bleeding by causing subsequent 
inflammation and fibrosis around the vessel wall while preserving vessel 
patency allowing for portal decompression and also preventing the 
formatin of collateral vessels. 
           Sarin et al, used a transparent Teflon injector with a needle for 
injection sclerotherapy. If after puncturing the varices, blood could be 
seen to flow up into the Teflon injector, it was taken as intravariceal 
injection. He concluded that intravariceal sclerotherapy was superior to 
paravariceal sclerotherapy in the control of active bleeding and for total 
variceal obliteration but paravariceal injection is associated with low 
recurrence rate. Hence a combination of intravariceal and paravariceal 
injection is superior to the above two. 
COMPLICATIONS OF SCLEROTHERAPY: 
EARLY 
 Dysphagia 
 Low grade fever 
 Retrosternal pain 
 Chest radiographic changes 
 Pleural effusion 
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DELAYED 
 Perforation 
 Mucosal ulceration 
 Esophageal strictures 
 Mediastinitis 
 Pneumothorax 
 Acute respiratory distress  syndrome 
 Fistulas 
 Pericarditis 
 Mesenteric venous thrombosis 
 Bacteremia 
 Esophageal motility disorders 
         Sclerotherapy is associated with a wide range of complications 
ranging from transient pyrexia to esophageal perforation leading to death. 
        Complications following slerotherapy depend upon the: 
 Nature of sclerosant used 
 Amount of sclerosant 
 Concentration of the drug 
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 Injection site 
 Time interval between the sessions 
      Minor complications like fever, retrosternal pain and dysphasia occur 
so frequently that these are considered as side effects and not as 
complications. 
ESOPHAGEAL COMPLICATIONS: 
 Esophageal ulceration occurs frequently following emergency 
sclerotherapy. Sarles included the most superficial ulcers too and arrived 
at 65% incidence of ulceration with 1% sodium tetradecyl sulphate. 
Conversly, Soderlund included only the ulcers that were associated with 
bleeding or were deep enough to prevent further sclerotherapy and 
reported an incidence of 25%. Japerson reported esophageal ulceration in 
77% and ulcerogenic bleeding in 15% 
 Following sclerotherapy with 1 % poidocanol. In the presence of 
deep ulcers, further injection should be deferred to prevent esophageal 
perforation.  
           Esophageal perforation is the most dreaded complication and has 
an incidence of 1-7 %.These patients may be managed non operatively 
with either enteral feeding or paraenteral hyper alimentation and a course 
of intravenous antibiotics. Sarles using 1.5% sodium tetradecylsulphate, 
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noted esophageal perforation  in 0.5% patients while Jasperson  reported  
3% incidence of perforation with the use of 1% polidocanol. 
          The incidence of esophageal strictures ranges from 0.9% as 
reported by Johnson with the use o ethanolamine oleate to 54% with the 
use of 3 % polidocanol. Soren high  rate  esophageal  stricture  was 
attributed to the frequency and amount of sclerosant used. 
        Transient substernal pain may occur in 55% of patients following 
sclerotherapy. The pain is due to inflammatory mediatinitis or esophageal 
spasm. Chronic dysphagia following sclerotherapy may be due to distal 
esophageal strictures but 4-6% is due to impaired motility.  
           Edophageal manometric studies show no decrease in esophageal 
sphincter pressure but shows marked abnormalities in esophageal 
peristalsis. Esophageal carcinoma has been reported in one case after 
undergoing nine sessions of sclerotherapy with 3 % polidocanol. 
REGIONAL COMPLICATIONS: 
          Pulmonary complications due to sclerotherapy range from 
asymptomatic changes on x ray to plural effusion, pneumonia and ARDS. 
Hughes reported 50% incidence of pleural effusion resolves 
spontaneously. Pneumonia occurs due to aspiration. The development of 
ARDS occurs with use of sodium morrhuate. Monroe discovered that 
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sodium morrhuate caused transient pulmonary hypertension associated 
with increased flow of protein poor lymph. 
SEPTIC COMPLICATIONS: 
          20-30% of patients had fever lasting for 24-48 hours following 
sclerotherapy. When fever lasts more than 2 days, the diagnosis of sepsis 
should be made. Transient bacteremia was reported in 15% of patients. 
Pneumococcus, streptococcus and staphylococcus were the commonest 
organisms isolated. The risk sepsis due to sclerotherapy was not related to 
the amount of sclerosant used, number of sessions or the cause of the 
liver disease. Sandy demonstrated a threefold increase in the incidence of 
bacteremia if the needle was inserted up to 5-7 mm instead of 3-5 mm. 
The incidence of clinically evident sepsis after sclerotherapy is low, so 
antibiotic prophylaxis for the patients undergoing sclerotherapy those 
who have significant valvular heart disease. 
  Other septic complications such as brain abscess, spontaneous 
bacterial peritonitis, perinephric abscess, purulent meningitis have also 
been reported. Other complications such as gastric ulcers, bleeding 
duodenal varices, portal vein thrombosis, colonic varices and mesenteric 
vein thrombosis have also been reported. 
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ENDOSCOPIC GLUE INJECTION: 
 Tissue adhesives are compounds that can be used for hemostasis, 
wound closure, or fistula repair. The main classes of tissue adhesives are 
cyanoacrylate glues, fibrin glue, and thrombin. Cyanoacrylate glues are 
used primarily for endoscopic control of bleeding from gastric varices 
and less commonly for hemostasis of other bleeding lesion 
 The tissue glue, N-butyl-2-cyanoacrylate, is a watery solution that 
polymerizes and hardens within 20 s in a physiological milieu and 
instantaneously on contact with blood. Because the rapid solidification of 
the glue makes endoscopic application technically difficult, it is necessary 
to dilute it with the oily contrast agent Lipiodol Ultra Fluid (Therapex, 
Canada). A 50/50 mixture of Histoacryl (B. Braun Melsungen AG, 
Germany) and Lipiodol is used for injection. 
 Patients with allergies to iodine should not receive this therapy 
because Lipiodol is an iodized oil emulsion. 
ENDOSCOPIC VARICEAL LIGATION: 
         Endoscopic variceal ligation was first introduced to esophageal 
varices in 1989 by Stiegmann and Goff. This technique is an adaptation 
of the similar banding ligation hemorrhoids. In contrast to sclerotherapy 
where chemical action is used, in variceal ligation obliteration of the 
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varices is caused by mechanical strangulation with rubber bands, because 
of its action on the suctioned, entrapped varices, the reaction is usually 
limited to the superficial esophageal mucosa. 
 Endoscopic variceal ligation is placement of the rubber ring over 
the variceal column which is then sucked into a plastic cylinder which is 
attached to the tip of the endoscope. 
 Previously single shot ligation was used. Multiple shot devices 
have replaced the previous one because of its simplicity and rapidity and 
also over tube is not recommended and hence preventing its serious 
complications related to its use. And also new transparent caps are 
available which improve the visibility. Several commercial multiband 
devices are available for EBL.Multiband devices have 4-10 bands. 
TECHNIQUE: 
 Diagnostic endoscopy is performed and varices are identified. The 
distance is measured from the mouth by the markings in the endoscope. 
The endoscope is withdrawn and is loaded with ligation devices. Devices 
is firmly attached to the scope and placed in neutral mode. Endoscopy 
with the loading device is passed which need little experience. Slight 
flexion of the neck, gentle and constant advancement of the scope with a 
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slight torque of the shaft right and left with visualization of the pharynx 
would guide it. 
 
Fig 12: Endoscopic Banding 
 After intubation the device is kept in forward only mode. Once 
varix is identified, the tip is pointed towards it and continuous suction is 
applied to the varices till it is filled in the cap. Smooth movement left and 
right will help it. Once the red out sign appears, band can be fixed. 
Usually the procedure is performed by starting from gastro esophageal 
junction and proceeding upwards in a spiral fashion to avoid 
circumferential placement at the same level which would increase the risk 
of stricture. 
  In case of active bleeding the visual field is restricted due to the 
cylinder attachment which makes the technique difficult to performed 
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thus requiring active flushing with water and suction repeatedly. The 
rubber band should be delivered at a point on the varices but if it is 
missed, banding of normal mucosa is not harmful compared to sclerosant 
injection, which may cause serious side effects. If the bleeding point is 
not identified, then multiple banding devices can be used to place 
multiple bands at gastro esophageal junction checking that no subcardial 
prolongation occurs.  
           This might reduce torrential bleeding and the band can be fixed 
upward. After application of rubber bands over the esophageal varices, 
the ligated tissues with the rubber band will fall off within 10 days. The 
variceal sloughing causes shallow esophageal ulcers at the ligated sites 
while the esophageal varices reduce in size. Thought the ligation induced 
ulcers have a greater surface area, they are shallower and hence heal more 
quickly than that are caused by sclerotherapy. 
 Liquid diet is started for the first 12 hours and then the patient is 
advised to have soft foods. A recent study tells that patients who received 
pantoprazole after elective EVL found to have smaller post-banding ulcer 
than the other patients who received placebo therapy on follow up 
endoscopy. But the symptoms and ulcer number remained the same. 
 Eradication of the esophageal varices requires 2-3 sessions of 
endoscopic variceal ligation. De Franchis and Primignani conducted a 
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meta-analysis in 1999 included 14 articles in which the mean number of 
sessions to obliterate varices was reduced from5.4 in patients receiving 
sclerotherapy to 3.6 in patients receiving endoscopic variceal ligation. 
Both the time interval between the sessions should be noted to improve 
the efficacy of banding. Varices is said to be obliterated if they either 
disappear or unable to grasp. 
 Eradication can be obtained in about 89% of subjects although 
recurrence is common. The major disadvantages is higher incidence of 
recurrent varices. But these recurrent varices can be treated by ligation. 
Moreover recurrent varices do not increase the chance of rebleeding and 
do not cause endoscopic difficulties. 
 A study from Japan described that EVL performed once in two 
months is better that that is performed once in two weeks regarding 
variceal occurrence. Because rebleeding rate is significantly reduced who 
received endoscopic therapy at early and who achieves variceal 
obliteration in a shorter period. The incidence of bacteremia and 
infectious sequelae are less in EVL compared to sclerotherapy. 
Endoscopic band ligation is an alternate to sclerotherapy with fewer 
complications but there are the below list of complications: 
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Complications: 
 Esophageal perforation 
 Esophageal ulceration 
 Retrosternal pain 
 Transient dysphagia 
 Gastropathy 
 Esophageal strictures 
 Ulcer bleeding 
 Bacteremia  
        The advantage of EVL is the low rate of treatment induced 
complications. This is because the quantity of tissue ligated is limited by 
the design of the device resulting in fewer complications involving the 
esophageal wall. 
          Complications of EVL are either due to the ligation procedure or 
from the use of the overtube. Retrosternal pain, transient dysphagia 
occurs frequently in the immediate post ligation period  and  is considered 
as side effects  rather  than complications. 
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ESOPHAGEAL ULCERATION: 
 The band ligation usually  produces  small  ulceration  and  rarely 
produces symptoms. They present as mucosal defects at the site of 
application of bands. Gimson et al, have reported esophageal ulceration 
in 35 out of 55 patients who had banding. 23 of them had small ulceration 
(size<5 mm) and 13 of them were having large (size >5 mm). Laine et al, 
has reported esophageal ulcerations producing rebleeding in 6% of 
patients who had undergone ligation. Steigmann has reported bleeding 
from ulcers in 12% of patients following ligation. 
 Young et al, compared the ulceration produced by ligation and 
sclerotherapy by means of scored ERCP cannula to measure the length, 
width and depth of ulcers in a randomized trial. Esophageal ligation 
produced shallow circular ulceration with large surface  area that resolved 
in 14.4 days. Sclerotherapy produced linear, deep ulceration with a 
smaller surface area that resolved in 20.9 days. 
 Van Vlierberghe et al, reported early rebleeding after ligation in 
patients with Child-Pugh class C cirrhosis. This was attributed to the 
impaired clotting function as a result of liver disease and the greater size 
of the ulcers due to ligation. 
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ESOPHAGEAL STRICTURES: 
  Esophageal ulcerations leading into strictures are less common 
following ligation than with sclerotherapy. Laine et al, in a Meta analysis 
of 7 randomized trials involving 547 patients found esophageal strictures 
in 7 patients. Another study by Laine et al, demonstrated a significant 
reduction in stricture formation in ligation when compared to 
sclerotherapy (35%). Low rates of strictures formation have been reported 
by Baronicin due to ligation (11%) when compared to sclerotherapy. 
Steigmann and Sarin also reported a lower incidence of stricture 
formation following ligations (2% and 0 %). 
ALTERATION OF ESOPHAGEAL MOTILITY: 
  In a study by Berner et al, 70% of patients had reported a transient 
dysphagia which lasted up to 24-72 hours after the procedure. This is due 
to the engorged banded varices. In a study conducted by Ming-Chih Hou 
et al, he compared the alteration of esophageal motility following 
sclerotherapy and ligation. He found that ligation produced a little change 
at 1 month or 3 month after eradication, while sclerotherapy produced a 
significant prolongation of transit time for 1 month after eradication 
which was reversible and improved after 3 months. 
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SYSTEMIC COMPLICATIONS: 
            Risk of bacteremia following ligation is 3-6% compared to 
sclerotherapy which is 5-53%. It is associated with fewer episodes of 
infectious sequelae such as spontaneous bacterial peritonitis or 
pneumonia. 
 Gin-Ho et al, reported that infectious sequelae due to sclerotherapy 
is about 20% compared to 1.9% in ligation. This is because the 
mechanical strangulation of varices during ligation obliterates the sub 
mucosal channels which diminish the entrance of bacteria into the blood 
stream. In a meta-analysis of 8 trials conducted by Laine et al, 7 out of 
525 patients had pulmonary infection and 6 had bacterial peritonitis 
which was significantly lower comparing sclerotherapy. 
OVERTUBE ASSOCIATED COMPLICATIONS: 
 In the past during endoscopic ligation using a single shot ligator the 
necessary repeated esophageal intubation with the scope is facilitated by a 
flexible plastic over tube passed over the endoscope. Majority of 
complications  reported following ligation are associated with the use of 
over tube. Over tube injury to pharynx  and proximal esophagus transient 
vocal cord paralysis, cricopharyngeal perforation, proximal esophageal 
perforation, varix rupture and free esophageal perforation have also been 
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reported. Mucosal injury had been reported in 72% of treatment sessions 
in one study. Massive bleeding has been reported distal to the over tube, 
probably due to blockage in venous outflow by the tube. 
 Esophageal perforation occurred with over the endoscope 
placement technique because of the large gap between the endoscope and 
the over tube which entrapped esophageal mucosa during the process of 
sliding the over tube over the endoscope during its insertion. Since the 
development of multiband ligator, not a single esophageal perforation has 
been reported. Banding is also associated with foods impaction resulting 
from a combination of lumen obstruction by banded varices and distal 
esophageal spasm. 
OTHER ENDOSCOPIC OPTIONS: 
TISSUE ADHESIVES (VARICEAL OBTURATION) 
 N-butyl-2-cyanoacrylate and isobutyl-2-cyanoacrylate have been 
used in the control of esophageal and gastric varices with control of 
bleeding in 80% of cases. Tissue adhesives were first used by 
Lunderquist in 1978 in treatment of varices. Cyanoacrylate is a 
hydrophilic tissue adhesive with a consistency similar to water. This is 
when added to blood rapidly polymerizes forming a solid cast of the 
injected vessels which results in rapid hemostasis of active bleeding and 
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prevents recurrence of bleeding. It has to be diluted with lipid based 
contrast agent to the dilution of about 2:1 ratio to delay the instantaneous 
polymerization within the injection syringe and needle. 
 Complications are due to embolisation of the glue producing 
cerebral stroke, pulmonary embolism, portal vein thrombosis, retro 
gastric abscess, visceral fistula and splenic infarction. Chances of damage 
to endoscope are high due to clogging of the accessory channel. There is 
also danger of eye injury due to accidental spraying of the cyanoacrylate. 
ENDOLOOPS: 
          Endoloops are detachable nylon snares initially developed to 
control post polypectomy bleeding. This technique has been applied for 
control of bleeding from esophageal varices  
                        
 
 
 
 
 
70 
 
MATERIALS AND METHODS 
 The study was conducted in the Department of General Surgery in 
collaboration with the Department of Medical Gastroenterology and 
Department of Vascular Surgery, Coimbatore medical College Hospital 
from June 2013- August 2015. This study was approved by the ethical 
committee of Coimbatore Medical College Hospital. 
STUDY POPULATION: 
           50 patients with portal hypertension who were admitted during the 
study period of  June 2013 -  august 2015 in medicine and surgery wards, 
with the complaints of hematemesis and/or malena, who had grade 3 and 
4 varices without gastric varices and other causes of upper GI bleeding in 
upper GI endoscopy were included in this study. 
RANDOMISATION: 
 Every alternative patients presenting with above history is divided 
into 2 groups. One group is treated with esophageal banding and other 
group is treated with 3 % Sodium tetradecyl sulphate after getting 
informed and written consent from the patient. 
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INCLUSION CRITERIA: 
 Age 21-70 years 
 Both sexes 
 Grade III and IV esophageal varices 
 Patients complaining with hematemesis and/or malena 
 Due to Portal Hypertension 
EXCLUSION CRITERIA: 
 Age <21 and >70 
 Grade I and II varices 
 Non portal hypertension causes of upper GI bleeding 
 Prior history of endoscopic treatment and shunt operation for 
varices 
 Presence of Hepatic Encephalopathy, Hepatorenal syndrome and 
life expectancy less than 48 hours 
 Patients with positive serology for Hepatitis B (HbsAg) and C 
virus (anti HCV) 
PROCEDURE: 
         Informed consent is obtained from the patient about the procedure. 
Patient is kept in NPO for 6 hours. Xylocaine spray is applied over the 
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posterior pharyngeal wall. Diagnostic endoscopy is performed. Presence 
of the culprit grade III and IV varices are identified and confirmed. 
GROUP I: 
 They are subjected to esophageal variceal banding. Diagnostic 
endoscopy is performed and varices are identified. The distance is 
measured from the mouth by the markings in the endoscope. The 
endoscope is withdrawn and is loaded with ligation devices. Device is 
firmly attached to the scope and placed in neutral mode. Endoscopy with 
the loading devices is passed.  
 After intubation the device is kept in forward only mode. Once 
varix is identified, the tip is pointed towards it and continuous suction is 
applied to the varices till it is filled in the cap. Once the red out sign 
appears, band can be fixed starting from gastro esophageal junction and 
proceeding upwards in a spiral fashion. 
GROUP II: 
 They are subjected to endoscopic sclerotherapy treatment. 
Diagnostic endoscopy is done and varices are identified. All visible 
varices are injected with 1-2 ml of 3% sodium tetradecyl sulphate below 
the bleeding site directly into the varices and the colour change in noted 
to confirm. Then the adjacent sub mucosa of the varices is injected with 1 
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ml of the sclerosant carefully upto 10 cm from Gastro esophageal 
junction proximally in a spiral fashion. 
 Care is taken that not more than 20 ml is injected in a single 
session to a patient. Three sessions were planned for every patient in an 
interval of 3 weeks. There after patients were reviewed once in a month 
for a period of three months. For each session the number of bands and 
the amount of sclerosant used are recorded. After the procedure all the 
patients are treated with beta blockers’. 
 During each visit, patients were assessed for complications such as 
retrosternal  pain, esophageal ulcers, strictures, pleural effusion and 
mediastinitis. 
 Esophageal ulcers are defined as depression in the mucosal surface 
with overlying injury exudates. They were classified as superficial if 
shallow and less than 2 cm in diameter and as deep if more than 2 cm 
with shaggy border and a grayish necrotic base. Chest x ray was taken if 
the patients had persistent pain for detection of pleural effusion or 
mediastinitis if symptoms warranted. 
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Dysphagia was defined as difficulty in swallowing food and was graded 
into 4 grades: 
 Grade I- Able to swallow both solid and liquid foods but was 
difficulty 
 Grade II-Able to swallow liquid foods but not solid foods 
 Grade III-Not able to swallow both solid and liquid foods 
 Grade IV- Absolute dysphgia including inability to swallow saliva 
 Esophageal strictures were diagnosed if the patients reported with 
dysphagia and had evidence of narrowing by endoscopy and barium 
swallow. The efficacy was assessed in terms of 
 Eradication of varices 
 Number of sessions for variceal eradication 
 Variceal recurrence 
 Rebleeding episodes prior to eradication 
 Associated complications 
           Variceal eradication was defined as the absence of visible 
variceal channels in the distal 5 cm of esophagus or presence of only 
mucosal tags. Variceal recurrence was defined as reemergence of 
variceal columns following previous complete eradication. 
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           Control of active hemorrhage was defined as absence of 
clinically detectable upper GI bleeding for 48 hours after endoscopic 
variceal ligation was performed for active bleeding. 
           Failure of therapy was defined as recurrent variceal bleeding 
after three endoscopic treatment sessions or during the course of 
therapy. 
STATISTICAL ANALYSIS: 
              Graph Pad Instat software was used for statistical analysis. 
Fisher’s exact test was used for comparing the outcomes of 
endoscopic band ligation therapy and sclerotherapy. A p value of<0.05 
was considered statistically significant. 
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SEX DISTRIBUTION
MALES
FEMALES
RESULTS 
       In this study population, 29 males and 21 females have undergone 
treatment for varices and the majority were in the age group of 31-50 
years 
 
. 
 
 
Fig13:   Sex distribution of the study population 
   AGE AND SEX DISTRIBUTION 
 
Fig14: Age and Sex Distribution of Study Populattion 
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Fig15:    Age and Variceal Grade Distribution of the Study Population 
As the age progresses grade IV varices was more common than grade III 
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Study group randomization: 
 Table 1:     Banding and sclerotherapy in bleeding varices 
ACTIVELY 
BLEEDING 
VARICES 
BANDING SCLEROTHERAPY TOTAL 
GRADE 
III 
GRADE 
IV 
GRADE 
III 
GRADE 
IV 
+ 6 4 5 7 22 
- 7 8 7 6 28 
TOTAL 13 12 12 13 50 
 
22 cases presented with actve bleeding during the procedure and 28 
patients were asymptomatic. Active bleeding was more common among 
male patients. 
 
Fig 16:   Randomization of Actively Bleeding Grade III Varices for 
Banding and Sclerotherapy 
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ACTIVE BLEEDING –GRADE IV VARICES 
 
Fig 17:Randomization of active bleeding grade IV varices for 
banding and sclerotherapy 
 
ACTIVE BLEEDING 
Fig18: Randomization of Actively Bleeding Varices for Banding and 
Sclerotherapy 
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NO OF BANDS & AMOUNT OF SCLEROTHERAPY USED 
Table2: Number of Bands and Amount of Sclerotherapy used 
GRADE ACTIVE 
BLEED 
TOTAL NO 
OF BANDS 
USED 
TOTAL AMT. OF 
SCLEROSANT 
USED(ml) 
        
     III 
+ 52 168 
- 42 120 
 
     IV 
+ 44 196 
- 46 120 
TOTAL  194 532 
     For grade III varices 94 bands and 188 ml of sclerosant used and for 
grade IV varices 100 bands and 216 ml of sclerosant used. 
 
                             Fig19: Number of Bands used 
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AMOUNT OF SCLEROSANT USED 
     
Fig20:  Amount of Sclerosant used 
       Number of bands and amount of sclerotherapy used are more in 
active bleeding when compared to non bleeding varices. 
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COMPLICATIONS: 
Table3: complications of banding ad sclerotherapy 
 
COMPLICATIONS BANDING SCLEROTHERAPY 
MALE FEMALE MALE FEMALE 
 %  %  %  % 
RETROSTERNAL 
PAIN 
3 10 3 15 5 16.5 6 30 
ODYNOPHAGIA 1 3.3 3 1 4 13.2 8 40 
FEVER 1 3.3 1 5 5 16.5 6 30 
TACHYCARDIA 0 0 2 10 3 10 5 25 
ESOPHAGEAL ULCER 3 10 3 15 9 29.7 4 20 
STRICTURE 0 0 0 0 1 3.3 0 0 
BLEEDING 2 6.6 1 5 1 3.3 0 0 
FAILURE 0 0 0 0 2 6.6 3 15 
                Males tolerated the procedure when compared to females. 
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RETROSTERNAL PAIN: 
TABLE 4: comparison of retrosternal pain in banding and sclerotherapy 
RETROSTERNAL 
PAIN 
BANDING SCLEROTHERAPY TOTAL 
PRESENT 6 11 17 
ABSENT 19 14 33 
TOTAL 25 25 50 
        Though retrosternal pain is seen in patients who underwent 
sclerotherapy association was not statistically significant.(p value-0.2321) 
 
Fig 21: Comparison of  Retrosternal Pain in Banding and 
Sclerotherapy 
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ODYNOPHAGIA: 
TABLE5:Comparison of odynophagia in banding and sclerotherapy 
ODYNOPHAGIA BANDING SCLEROTHERAPY TOTAL 
PRESENT 4 12 16 
ABSENT 21 13 34 
TOTAL 25 25 50 
Twelve patients in sclerotherapy group had odynophagia. However there 
is no statistically significant difference between two groups. (p value-
0.0322) 
 
Fig22:    Comparison of Odynophagia in Banding and Sclerotherapy 
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FEVER: 
           Table 6: Comparison of fever in banding and sclerotherapy 
FEVER BANDING SCLEROTHERAPY TOTAL 
PRESENT 2 11 13 
ABSENT 23 14 47 
TOTAL 25 25 50 
 
     Fever is most common in patients who had sclerotherapy while only 
two patients developed fever following banding and this is statistically 
significant (p value 0.0083) 
Fig23:    Comparison of Fever in Banding and Sclerotherapy 
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TACHYCARDIA 
           Table 7: comparison of tachycardia in banding and sclerotherapy 
TACHYCARDIA BANDING SCLEROTHERAPY TOTAL 
PRESENT 2 8 10 
ABSENT 23 17 40 
 TOTAL 25 25 50 
The two study groups did not have statistically significant difference in 
tachycardia  
(p value 0.0738) 
 
Fig24: Comparison of Tachycardia in Banding and Sclerotherapy 
 
0
5
10
15
20
25
banding sclerotherapy
present 
absent
87 
ESOPHAGEAL ULCER: 
        Table 8: comparison of ulcer in banding and sclerotherapy 
ESOPHAGEAL ULCER BANDING SCLEROTHERAPY TOTAL 
PRESENT 6 13 19 
ABSENT 19 12 31 
TOTAL 25 25 50 
 Esophageal ulcer was seen more in patients who underwent 
sclerotherapy but the association was not statistically significant ( p value 
0.0792) 
 
Fig25: Comparison of Esophageal ulcer in Banding and 
Sclerotherapy 
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ESOPHAGEAL STRICTURE: 
Table 9: comparison of stricture in banding and sclerotherapy 
STRICTURE BANDING SCLEROTHERAPY TOTAL 
PRESENT 0 1 1 
ABSENT 25 24 49 
TOTAL 25 25 50 
   Only those patients who underwent sclerotherapy developed esophageal 
stricture, still it is not statistically significant ( p value 0.3124) 
 
Fig26: Comparison of Stricture in Banding and Sclerotherapy 
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REBLEEDING 
REBLEEDING BANDING SCLEROTHERAPY TOTAL 
PRESENT 3 1 4 
ABSENT 22 24 46 
TOTAL 25 25 50 
     Rebleeding was more common in patients who underwent 
banding.However this difference was not statistically significant( p value 
0.6022) 
 
Fig27: Comparison of Rebleeding in Banding and Sclerotherapy 
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FAILURE 
 Table 11: comparison of failure in banding and sclerotherapy 
FAILUR BANDING SCLEROTHERAPY TOTAL 
+          0                6           6 
_         25              19         44 
TOTAL         25               25         50 
      Failure is more common in patients who underwent sclerotherapy (p 
value 0.0223) 
 
 Fig28: Comparison of Failure in Banding and Sclerotherapy 
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DISCUSSION 
 The improvement in the results of the treatment of the variceal 
bleeding might be attributed to better clinical management of the above 
patients. Although in most of the studies performed, sclerotherapy is 
found to be inferior to band ligation for primary and secondary 
prophylaxis for variceal bleeding and also with lot of complications 
compared to banding some studies suggest that both are equally 
efficacious in the treatment of the esophageal varices. In 1986, Steigmann 
and his colleagues introduced band ligation which acts by mechanical 
action by causing strangulation of the variceal cord resulting in necrosis 
and scar formation 7-10days later. The difference in the technique is 
provided by number of bands used. Up to 10 bands can be used in a 
single session. 
 Since this procedure is easy to perform, results are often 
reproducible without variations. The difficult is that ligation of small 
varices is tedious. But in case of variceal injection of sclerotherapy, 
which was the first endoscopic treatment used approximately 50 years 
before the band ligation, there are numerous variations including the type 
of sclerossant, concentration of the agent, sclerosing technique, injected 
volume and location of the sclerosant (paravariceal and intravariceal 
combined) which is the reason for heterogeneous results of sclerotherapy 
92 
 
presented in different publication. And also this technique requires more 
experience and significant skill of the endoscopist and hence this 
technique is more operator dependent technique rather than banding. 
Hence  the concept of combining ligation with  sclerotherapy by 
employing ligation when the varices are large and converting to 
sclerotherapy when the varices becomes smaller has been put forward to 
maximize the benefits of  both the technique  and minimize the 
complications associated with each other. 
 But most of the studies which compared ligation and sclerotherapy 
with ligation alone showed no greater benefits.26-28 A total of 40 patients 
included in the present study, 50% of the patients are in the age group of 
31-50 years. Cirrhosis was the most common cause for portal 
hypertension. This was followed by non cirrhotic portal fibrosis and extra 
hepatic portal vein obstruction.  
 In the present study, only the patients who had either grade III or 
grade IV varices at presentation are included. Since patients with grade I 
and grade II were not considered for ligation because of technical 
difficulty in banding. 
 Most of the patient had cirrhosis had their etiology while the others 
had extra hepatic portal venous obstruction. 
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CONTROL BLEEDING: 
 A Metanalysis is done comparing the use of band ligation and 3% 
sodium tetradecyl sulphate and was published in 2006 and consists a total 
of 11 studies with a total of 1320 patients. The efficacy of endoscopic 
band ligation for initial hematemesis was found to be an average of 98% 
while that of the endoscopic sclerotherapy was found to be an average of 
96%. Despite the better results obtained in the control of bleeding in band 
ligation than sclerotherapy, there is no difference in the mortality noted. 
In the present study, the efficacy of banding is 96% and that of 
sclerotherapy is 89%. This excellent control of varicel bleeding is 
comparable to other reports has been mentioned by many authors that 
during active bleeding, presence of fresh blood and blood clots obscures 
the vision leading to difficulty in banding. In this study about 25 patients 
had active bleeding. In that 10 were subjected to banding, 10 were 
subjected to sclerotherapy. About 2 patients had rebleeding in banding 
and 3 patients had rebleeding who were subjected to sclerotherapy. 
VARICEAL ERADICATION: 
 Several studies on ligation have reported successful eradication of 
varices in 50-95% of patients. Steigmann et al, reported an eradication 
rate of 52% with ligation with a median of 5 treatment sessions and 15 
ligation per patient.  
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  Laine et al , in their study of 39 patients who underwent ligation 
reported 58% of eradication with a median of 4 treatment sessions at an 
average of 3.9 bands at each session.21 Gimson et al, reported zn 
eradication rate of 70% in patientswho underwent ligation with a median 
of 3.4 endoscopic sessions. Sarles et al, reported 28% obliteration rate. In 
another study, variceal obliteration was achieved in 54% of patients who 
were treated with sodium tetradecyl sulphate. Despite these old studies, 
new studies such as Bhargava et al, reported eradication in 87% of 
patients at  a median of 6 5 endoscopic sessions and also showed 88% 
eradication rate in use of sodium tetradecyl sulphate.30 
 The King,s college study reported a satisfactory eradication of 
esophageal varices by the use of banding with less complication than 
sclerotherapy although much of the the complications are strictures. A 
study conducted by Grimson and Ramage et al , with an aim to find 
whether endoscopic variceal ligation is more effective in eradicating 
varices than sclerotherapy showed that both the techniques were effective 
in controlling the bleeding(92% for banding and 91% for 
sclerotherapy).variceal obliteration was not achieved in some patients in 
each group(3% banding and 6% sclerotherapy). Though there was no 
significant difference between the above two techniques in eradication, 
ligation achieved more quickly than sclerotherapy. Thus in newer studies, 
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the efficacy of both band ligation and sclerotherapy in eradicating the 
varices have increased a lot. This have multiband ligating devices rather 
than single band ligating devices. In the present study of about 50patients, 
25 were treated by endoscopic variceal leading and other 25 by 
endoscopic sclerotherapy (3% sodium tetradecyl sulphate), the 
eradication of varices by banding was 100% while that of sclerotherapy 
was only 80%. 
 As the most of the previous studies, the present study also suggests 
that the endoscopic variceal banding is superior to sclerotherapy in the 
eradication of varices. 
COMPLICATIONS: 
 Most of the studies suggest that the main advantage of ligation over 
sclerotherapy is the low rate of complications. Laine et al, have reported 
complication in 24% of patients who had ligation. ALTraif et al, have 
reported a complication rate of 60% using sclerotherapy.28 In the present 
study, the complications’ were found in 30 to 50 patients among whom 
the majorities were esophageal ulceration, retrosternal pain, odynophagia, 
fever and tachycardia. Similar observations were made out in most of the 
studies. The patients who had active bleeding during the procedure had 
more complication rate. 
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ESOPHAGEAL ULCER: 
 Esophageal ulcer was the commonest complication following 
sclerotherapy in most of other studies. The occurrence of post 
sclerotherapy ulceration was attributed to the higher volume of sclerosant 
per session, shorter interval between sclerotherapy sessions, and higher 
volume of sclerosant and nature of the sclerosant used. In case of banding 
large superficial ulcerations are common due to necrosis. Esophageal 
ulceration was reported in 36% of patients who had undergone ligation by 
Gimson et al, in the study of 54 patients.21 Korula et al, had also shown 
similar reports- 70% of patients who had sclerotherapy. Blenkinsopp et al 
, showed that diluting sodium tetradecyl sulphate from 3 % to 1 % reduce 
the rate of ulceration with only a minimal decrease in efficacy. Westaby 
et al m compared the effect of sclerotherapy at one weekly interval and at 
three weekly intervals and found that ulceration is common at one weekly 
interval. 
 In present study, the esophageal ulceration is found to be the most 
common complication of both banding and sclerotherapy. 6 out of 25 
patients had esophageal ulceration who underwent variceal banding while 
13 patients of 25 had esophageal ulceration who underwent sclerotherapy. 
Thus 25% of patients who had banding and about 50% of patients who 
had sclerotherapy developed esophageal ulceration.  
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 All ulceration was found to be superficial without bleeding. The 
higher incidence of ulceration in the sodium tetradecylsulphate group was 
probably due to concentration used (3%) and also due to ulcerogenic 
property of sodium tetradecyl sulphate. 
RETROSTERNAL PAIN: 
 Transient retrosternal pain following sclerotherapy can be due to 
mediastinitis and due to esophagitis. Korula et al, reported an incidence 
of 24% with 1.5% sodium tetradecyl sulphate.31 In a study done by 
Lebski et al, the banding is associated with about 40% of patients 
developed retrosternal pain among which 6 out of 25 patients who 
underwent banding and 11 of 25 patients who underwent sclerotherapy 
had retrosternal pain. 
ODYNOPHAGIA: 
  In a study Berner et al, 75% of patients had reported a transient 
dysphagia which lasted upto 24-72 hours after the procedure. This is due 
to the engorged banded varices. Bargava et al, noted that dysphagia 
significantly common with sclerotherapy with sodium tetradecylsulphate. 
In the present study also, odynophagia is more commonly seen in sodium 
tetradecyl sulphate. In the present study also, odynophagia is more 
commonly seen in sodium tetradecyl sulphate group than banding group. 
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 The difference was statiscally significant. Edema and inflammation 
around the ulcer contributes to the narrowing of esophagus. This explains 
why dysphagia is more common in use of sclerotherapy because of its 
ulcerogenic property. Hence around 4 patient of 25 who underwent 
banding and 12 of 25 patients who underwent sclerotherapy had 
dysphagia with the significant ‘p’  
FEVER: 
 In most of studies, fever lasting for 24-48 hours after sclerotherapy 
and banding occurred in 20-40% of patients. Fever usually subsided 
spontaneously. In the present study, fever was seen in 8 % of patients 
who underwent banding and 44% of patients who underwent 
sclerotherapy with significant ‘p’ value. Most of the other studies have 
shown similar report with present study. 
TACHYCARDIA: 
 Tachycardia following banding and sclerotherapy could be due to 
febrile spikes or anxiety by the procedure. Kumar at al, reported 
tachycardia in 48% of patients with 3% sodium tetradecyl sulphate. In the 
present study 32% of patients who underwent sclerotherapy had 
tachycardia while only 8 % patients who underwent banding had 
tachycardia. 
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ESOPHAGEAL STRICTURE:             
 Esophageal strictures are due to healing of deep esophageal 
ulceration. Bargava et al , reported an incidence of 27% of strictures with 
1.5% sodium tetradecyl sulphate. Sorensen used 3% sodium tetradecyl 
sulphate and reported strictures in 35% of patients. He attributed this 
higher rate to frequent sclerotherapy sessions. Most of other studies 
reported strictures rate ranging from 1-20%. Laine et al, in a meta-
analaysis of 7 randomized trials involving 547 patients found esophageal 
strictures in 7 patients. Another studyby Laine et al, demonstrated 
significant reduction in stricture formation in ligation. Low rates of 
stricture formation have been reported by Baronicin et al, due to ligation 
compare to sclerotherapy. Steigmann and Sarin also reported a lower 
incidence os stricture following ligation. In the present study only one 
patient developed stricture following sclerotherapy  after 4 months . while 
no patient develop stricture following banding. This is due to proper 
banding technique in spiral fashion and restricting  sclerotherapy to 
proximal OG junction. 
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SUMMARY 
 This study is conducted prospectively on total of 50 patients with 
bleeding esophageal varices from September 2013  to august 2015 with 
the prime aim of evaluating  the efficacy and safety of endoscopic 
variceal banding and endoscopic sclerotherapy. 
 In this study cirrhosis is the most common etiology of portal 
hypertension accounting for 90% of study population. 
 60 % of the population were in 31-50 years of age group 
 In this study more than 70% of old age people presented grade IV than 
grade III varices 
 In this study 45% of patients had signs of active bleeding 
 In actively bleeding varices, sclerotherapy has a little added advantage 
over banding because of the technical difficulty of the banding due to 
obscured field. 
 In this study about 194 bands and 532 ml of sclerosant were used wth 
a mean of 7.76 bands and 21.2 ml of sclerosant per person. 
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 In active bleeding varices the mean number of bands and the amount 
of sclerotherapy is more compared to that of mean of number of bands 
and amount of sclerotherapy in non-bleeding patients. 
 In this study more number and percentage of females had 
complications compared to males though the study population of 
females is less 
 24% of patients had retrosternal pain in banding while 44%of patients 
in sclerotherapy had retrosternal pain 
 16% of patients with banding and 48% of patients with sclerotherapy 
had odynophagia 
 22% of patients with banding and 44% of patients with sclerotherapy 
had fever 
 32% of patients with sclerotherapy had tachycardia. No patients with 
banding complained of tachycardia 
 24%of patients with banding and 52% of patients with sclerotherapy 
had esophageal ulceration 
 4% of patients with sclerotherapy developed stricture. No patients 
with banding developed stricture over the follow up period. 
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 12% of patients with banding and 3% of patients with sclerotherapy 
had rebleeding during and after the procedures 
 20% of patients with sclerotherapy had recurrences of varices while no 
recurrence was seen in banding for the follow up period 
 ‘P’ value is significant in complications such as odynophagia,fever 
and recurrence 
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CONCLUSION 
 Both banding and 3% sodium tetradecyl sulphate are equally 
effective in controlling acute variceal hemorrhage among which 
sclerotherapy had a small advantage and also in preventing 
rebleeding. 
 Both banding and sclerotherapy are effective in eradicating varices 
but banding is more efficacious 
 Both banding and sclerotherapy have their side effects but 
sclerotherapy has more frequent and dreaded complications. 
 Hence banding is superior to sclerotherapy both in efficacy and 
safety 
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ABBREVIATIONS 
 
DSRS - Distal Splenorenal shunt 
EBL  - Endoscopic band ligation 
EVL  - Endoscopic variceal ligation 
GIT  - Gastrointestinal tract 
GEJ  - Gastroesophageal junction 
HVPG - Hepatic venous pressure gradient 
PTFE  - Polytetrafluroethylene 
STD  - sodium tetradecyl sulphate 
TIPS  - Transjugular intrahepatic portosystemic shunt 
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ANNEXURE-1 
PROFORMA 
Serial Number: 
        Name:                                                             Sex: 
        Age:                                                                Ward: 
        Hospital no: 
        Address: 
D.O.A                                         D.O.D                                D.O.S 
I. PRESENTING COMPLAINTS 
         Hemetemesis: 
         Malena: 
         Jaundice: 
         Fever: 
         Abdominal pain: 
         Abdominal distension: 
         Altered sensorium: 
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         Pedal edema: 
         Drug intake: 
II. PAST HISTORY 
       Hemetemesis:                                          Hypertension: 
        Malena:                                                   PREVIOUS TREATMENT 
        Jaundice: 
        Alcoholism: 
III. EXAMINATION 
         Built and Nourishment :                                     Icterus: 
          Mental status:                                                                        
 Cyanosis: 
          Pallor:                                                                                     
 Clubbing: 
         Lymphadenopathy: 
         E/o Liver failure: 
PR:                          Temp:                              RR:                                BP: 
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P/A: 
        Distension:                                     Abdominal veins: 
        Liver:                                             Spleen: 
        Ascitis: 
        Respiratory system: 
        CVS: 
IV:INVESTIGATIONS: 
Hb: Platelet count: 
TC: Peripheral smear: 
DC:  
Blood Urea: Blood sugar: 
Na/k: Hbs Ag: 
Sr.Bilirubin: SGPT: 
SGOT: Sr.Alk.PO4: 
USG of Abdomen: 
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V.TREATMENT 
       Date: 
       Grade of columns: 
       No. of. Columns: 
        No. of bands applied: 
        Amount of sclerosant injected: 
VI: COMPLICATIONS: 
       Retrosternal Pain: 
       Odynophagia: 
       Fever: 
       Tachycardia: 
       Esophageal ulcer: 
       Esophageal perforation: 
       Pleural Effusion: 
       Mediastinitis: 
       Rebleed: 
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FOLLOWUP 
SESSION 1 2 3 FOLLOW UP 
DATE      
GRADE      
NO.OF.COLUMNS      
NO.OF.BANDS 
APPLIED 
     
AMOUNT OF 
SCLEROSANT USED 
     
COMPLICATIONS      
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S.N
O NAME 
A
GE 
S
E
X 
IP.NO DIAGNOSIS GRADE 
BLEE
DING 
NO OF BANDS 
PER SESSION 
RETROST
ERNAL 
PAIN 
ODYNOP
HAGIA 
FEVE
R 
TACHYCA
RDIA 
ULCE
R 
STRICTU
RE 
REBLEEDIN
G FAILURE 
I II III 
1 Amaravathy 36 F 52652 Cirrhosis III + 6 3 1 + + - - + - - - 
2 Srinivasan 50 M 56321 Cirrhosis III - 5 1 - - - - - - - - - 
3 Neelaveni 55 F 59165 EHPVO IV - 5 1 - - - - - - - - - 
4 Ganesh 48 M 48562 Cirrhosis III + 6 2 1 - - - - - - - - 
5 Rukmani 48 F 52689 Cirrhosis IV + 6 3 2 + - + + + - - - 
6 Ramathal 48 F 54265 Cirrhosis IV + 6 4 1 - - - - - - - - 
7 Kasi 51 M 58659 Cirrhosis IV - 5 1 - - - - - - - - - 
8 Bannari 42 F 54896 Cirrhosis III - 5 1 - - - - - - - - - 
9 Karpagam 28 F 42658 Cirrhosis III + 6 2 - - - - - - - - - 
10 Kalyani 24 F 54896 EHPVO III - 5 1 - - - - - - - - - 
11 Kanmani 69 F 56325 Cirrhosis IV - 5 1 - - - - - - - - - 
12 Palanisami 52 M 52566 Cirrhosis IV + 5 1 - - - - - - - - - 
13 Rajendran 42 M 54236 Cirrhosis III + 6 2 - - - - -- - - - - 
14 Arul 40 M 51123 Cirrhosis IV - 6 4 1 + - - - + - + - 
15 Kumar 40 M 52654 Cirrhosis III - 5 1 - - - - - - - - - 
16 Sivagami 50 F 52314 Cirrhosis IV + 6 3 2 + - - + + - + - 
17 Kalimuthu 35 M 54865 Cirrhosis III - 5 1 - - - - - - - - - 
18 Raman 55 M 52231 Cirrhosis IV - 5 - - + - + - + - - - 
19 Neelamani 40 F 51265 Cirrhosis III + 5 4 - + - - - + - - - 
20 Ravikumar 53 M 53265 Cirrhosis IV - 5 - - - - - - - - - - 
21 Jaganathan 36 M 51426 Cirrhosis III - 5 1 - - - - - - -- - - 
22 Vimal 22 M 59624 EHPVO IV - 5 1 - - - - - - - - - 
23 Vinoth 38 M 57465 Cirrhosis IV - 5 1 - - - - - - - - - 
24 Karthikeyan 26 M 51232 EHPVO IV + 6 2 1 - - - - - - + - 
25 Lakshmi 55 F 52539 Cirrhosis III - 5 1 - - - + - - - - - 
MASTER CHART 
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S.N
O NAME 
A
GE 
S
E
X 
IP.NO DIAGNOSIS 
G
RA
DE 
BLE
EDIN
G 
SCLEROSANT  
USED PER 
SESSION 
RETROS
TERNA
L PAIN 
ODYNOP
HAGIA FEVER 
TACHYCA
RDIA 
ULCE
R 
STRICTU
RE 
REBLEEDIN
G FAILURE 
I II III 
1 Rajan 65 M 51236 Cirrhosis III + 16 9 8 + - + - + - - - 
2 Rangammal 60 F 51254 Cirrhosis IV - 13 8 5 + + + + - - - - 
3 Chandran 41 M 52526 Cirrhosis IV - 10 8 6 - - - - + - - - 
4 Zubair 40 M 53265 Cirrhosis III + 15 11 8 + + - - + - - - 
5 Ganesh 39 M 58965 Cirrhosis IV + 10 10 8 - - - - - - - - 
6 Palani 58 M 54126 Cirrhosis IV - 11 5 2 - - - - - - - - 
7 Marathal 43 M 52369 Cirrhosis IV + 15 8 5 + + + + + - - + 
8 Muniyandi 50 M 54756 Cirrhosis III _ 11 5 2 + + + + - - - - 
9 Lakshmi 60 F 51512 Cirrhosis IV - 16 7 4 + + + + - - - - 
10 Poongothai 33 F 52645 Cirrhosis III - 10 3 0 - + + + - - - - 
11 Natraj 43 M 54754 Cirrhosis IV + 17 9 6 + + - - + - - - 
12 Sundaram 50 M 52516 Cirrhosis IV + 11 7 6 - - - - + - - - 
13 Sugapriya 24 F 53146 EHPVO IV _ 16 10 9 - + - - + - - - 
14 Venugopal 65 M 58951 Cirrhosis III + 13 10 5 - - + + + + - - 
15 Sarojini 40 F 52468 Cirrhosis IV _ 10 2 0 + + - - - - - - 
16 Selval 65 F 52516 Cirrhosis III - 8 2 3 - - - - - - - = 
17 Poovathal 50 F 54326 Cirrhosis IV + 10 6 4 + + + + - - - + 
18 Sekar 33 M 59564 Cirrhosis IV - 14 9 3 - - - - + - - - 
19 Eswari 40 F 54216 Cirrhosis III + 9 5 1 - - + - - - - - 
20 Jeyalakshmi 46 F 52365 Cirrhosis III - 12 5 3 + + - - - - - - 
21 Ravi 48 M 56896 Cirrhosis III - 15 10 9 + + - - + - + + 
22 Natraj 52 M 55565 Cirrhosis IV - 14 12 5 - - + + + - - + 
23 Niwas 26 M 52231 EHPVO IV - 11 3 1 - - + - - - - - 
24 Vasanth 36 M 54465 Cirrhosis III + 10 11 7 - - - - + - - - 
25 Thenmozhi 28 F 53326 EHPVO III - 10 3 1 - - - - + - - - 
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nkw;bfhs;Sk; "A COMPARATIVE STUDY OF ESOPHAGEAL 
VARICES – BANDING VS SCLEROTHERAPY” vd;w 
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